Susceptibility of lung cancer patients to COVID-19: A review of the pandemic data from multiple nationalities.

Abstract

Several studies have highlighted that cancer patients tend to be more susceptible to develop severe infection and to die from COVID‐19. Certain medical conditions such as immunosuppression, presence of comorbidities, and underlying pulmonary damage are possible determinants of disease severity, especially in lung cancer patients. While recent studies have shown that lung cancer is one of the most prevalent tumor types among COVID‐19 cancer patients, we still have an incomplete view of how data from several countries work as a whole. The aim of this review was to investigate COVID‐19 prevalence in lung cancer patient cohorts and their probability to develop severe illness and death when compared to nonlung cancer patients from multiple nationalities, including countries that have been the epicenters of the pandemic. We also focus on some intrinsic lung cancer features that might influence COVID‐19 outcomes. An integrative view of the susceptibility of lung cancer patients might be especially relevant to assist physicians in evaluating the risks of COVID‐19 in these patients, and to foster better decisions on treatment delay.